Home > Analytics > SYNCOM FORMULATIONS (INDIA)

SYNCOM FORMULATIONS (INDIA)
Intrinsic Value | Fundamental Analysis

BOM : 524470     NSE :     
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : None or < 25%
Dec 08,2022
Price(EOD): ₹ 7.97
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 749.18 Cr
Value of ₹ 1 Lac invested in SYNCOM FORMULATIONS (INDIA)
on Dec 08,2017 (price: ₹ 2.17)

₹ 1 L

₹ 3.67 L

1W : 0.5% 1M : -0.4% 1Y : -16.1%
COMMUNITY POLL
for SYNCOM FORMULATIONS (INDIA)
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
SYNCOM FORMULATIONS (INDIA) 0.5% -0.4% -16.1%
SUN PHARMACEUTICAL INDUSTRIES -5.7% -3.1% 38%
DIVIS LABORATORIES -2.7% -0.3% -28.2%
DR REDDYS LABORATORIES -3.5% -4.1% -3.1%
CIPLA -0.5% -2% 23.4%
GLAND PHARMA -0.3% -3% -52.5%
PIRAMAL ENTERPRISES 1.3% -2% -65.1%
CADILA HEALTHCARE -1% -8.2% -10.5%
TORRENT PHARMACEUTICALS 0.3% -1.7% 10.8%

FUNDAMENTAL ANALYSIS OF SYNCOM FORMULATIONS (INDIA)

 
Fundamentals Score
[ Q(TTM): Sep2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF SYNCOM FORMULATIONS (INDIA)

 
Valuation Score
[As on : Dec 08,2022 ]

Ratio Standalone
P/E
P/B
P/S
46.15
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 16.24 Cr
[Latest Qtr - Sep2022 - Standalone Results ]

3.45
P/B Calculated based on Book Value of Rs 217.18 Cr
[Latest Year - Mar2022 - Standalone Results ]

3.38
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2022 - Standalone Results ]

Financial Ratios →

Insights 💡 There are potential 15% undervalued companies ! Discover More →

FAIR VALUE OF SYNCOM FORMULATIONS (INDIA)

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
1039%
293%
340%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SYNCOM FORMULATIONS (INDIA)



SYNCOM FORMULATIONS (INDIA) vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SYNCOM FORMULATIONS (INDIA)

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.27
0.35
0.01
0.21
-
-
-
-
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SYNCOM FORMULATIONS (INDIA)

Pledged Promoter Shares
0 %
As on : Sep2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SYNCOM FORMULATIONS (INDIA)

Standalone Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
6.01%
23.06%
8.09%
-6.96%
2.94%
-24.33%
-26.45%
-35.99%
QtrlyTrend
0
Latest Qtr: Sep2022
Quarterly Result Analysis →


SYNCOM FORMULATIONS (INDIA) related INDICES

BSE Indices1W1M1Y
S&P BSE SMALL CAP 0.5% 1.9% 5.1%
S&P BSE MIDSMALLCAP 0.5% 1.7% 4.6%
S&P BSE ALLCAP -0.5% 1.8% 7.5%
S&P BSE HEALTHCARE -2.5% -2.8% -7.2%
No NSE index found

You may also like the below Video Courses


FAQ about SYNCOM FORMULATIONS (INDIA)


Is SYNCOM FORMULATIONS (INDIA) good for long term investment?

As on Dec 08,2022, the Fundamentals of SYNCOM FORMULATIONS (INDIA) look Poor and hence it may not be good for long term investment ! See Financial Performance of SYNCOM FORMULATIONS (INDIA) . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SYNCOM FORMULATIONS (INDIA) UnderValued or OverValued?

As on Dec 08,2022, SYNCOM FORMULATIONS (INDIA) is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) ?

As on Dec 08,2022, the Intrinsic Value of SYNCOM FORMULATIONS (INDIA) is Rs. 1.81 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 0.70
Fair Value [Median EV / Sales Model] : Rs. 2.03
Fair Value [Median Price / Sales Model] : Rs. 1.81
Estimated Median Fair Value of SYNCOM FORMULATIONS (INDIA) : Rs. 1.81

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SYNCOM FORMULATIONS (INDIA) trading at a Premium or Discount?

As on Dec 08,2022, SYNCOM FORMULATIONS (INDIA) is trading at a Premium of 341% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].